Peak Bggr Inside ReCode’s New-in-Class Approach to Treating Cystic Fibrosis | BioSpace biospace.com ReCode CEO & President, David J. Lockhart/Photo courtesy of ReCode Therapeutics Last week, at the 44th European Cystic Fibrosis Conference (ECFS), …
Peak Bggr Rival Drugs of Biogen’s Aduhelm May Help Prove FDA’s Highly Criticized Approval | BioSpace biospace.com Photo courtesy of Biogen. The approval of Biogen's Alzheimer’s drug, now marketed as Aduhelm, has been a continuing controversy across the nation. From …
Peak BggrSerum Institute Of India India’s Vaccine Makers Are Pandemic Profiteers, Not Humanitariansverified_publisher The Intercept - Aparna Gopalan In April, a deadly Covid-19 surge overtook India as the country’s overflowing hospitals and crematoria made global headlines. While new daily cases …
Peak BggrEli Lilly 2 Stocks That Could Be Winners in Alzheimer's Disease Along With Biogenverified_publisher The Motley Fool - Keith Speights and Brian Orelli, PhD One is Biogen's partner. The other is a potential rival. Biogen (NASDAQ:BIIB) stock skyrocketed after its Alzheimer's disease drug Aduhelm won U.S. …
Peak BggrCancer Ziopharm: A Wait-And-Follow Style Biotechnology Investment (NASDAQ:ZIOP)verified_publisher Seeking Alpha - Gunner Laine Hardy Introduction: What is ZIOPHARM Oncology, Inc.? ZIOPHARM Oncology, Inc. (ZIOP) is a struggling non-revenue producing early clinical-stage …
